About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Down 0.28 (1.06%)
Data as of 06/19/19 3:07 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $26.03 with a 52 week high of $29.62 and a 52 week low of $11.08.

Recent News

Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers - 06/03/19
Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness SAN CARLOS, Calif., June 3, 2019 /PRNewswire/ -- A new study demonstrates the ability of Natera's Signatera™ test ... More»
Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test - 05/21/19
Represents Major Commercialization Milestone SAN CARLOS, Calif., May 21, 2019 /PRNewswire/ -- Noridian, the Medicare Administrative Contractor (MAC) for California-based laboratories, has posted a favorable draft local coverage determination (LC... More»
Natera Reports First Quarter 2019 Financial Results - 05/09/19
SAN CARLOS, Calif., May 9, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2019 and provi... More»
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier - 05/09/19
JAMA Oncology Study Suggests Potential for Natera's Signatera Test to Guide Treatment Decisions After Surgery SAN CARLOS, Calif., May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ test identified colorectal cancer r... More»
Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards - 05/07/19
Journal of Clinical Oncology Study Shows Natera's Test is Highly Prognostic and Effective for Recurrence Detection SAN CARLOS, Calif., May 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced the publication of a clinical validati... More»

Upcoming Events

There are currently no events scheduled.
Shareholder Tools